Cargando…

Efficacy and Safety of intravenous monoclonal antibodies in patients with moderate-to-severe active Graves’ophthalmopathy: a systematic review and meta-analysis

BACKGROUNDS: The effects of various treatments on Graves’ ophthalmopathy (GO) have been studied. As monoclonal antibodies (mAbs) have been proposed for the treatment of moderate to severe GO, direct comparisons between different mAbs are lacking.We therefore conducted this meta-analysis to objective...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hu, Yu, Chen, Jinhua, Lin, Ken, Yu, Xijie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Endocrinology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10242093/ https://www.ncbi.nlm.nih.gov/pubmed/37288301 http://dx.doi.org/10.3389/fendo.2023.1160936

Ejemplares similares

Corticosteroids in Moderate-To-Severe Graves’ Ophthalmopathy: Oral or Intravenous Therapy?
por: Penta, Laura, et al.
Publicado: (2019)

Severe Grave's Ophthalmopathy–missed for many years
por: Wani, Mohd Maqbool, et al.
Publicado: (2010)

Current insights of applying MRI in Graves’ ophthalmopathy
por: Song, Cheng, et al.
Publicado: (2022)

Association of variant on the promoter of cluster of differentiation 74 in graves disease and graves ophthalmopathy
por: Liu, Yu-Huei, et al.
Publicado: (2020)

Cytokines as Targets of Novel Therapies for Graves’ Ophthalmopathy
por: Fallahi, Poupak, et al.
Publicado: (2021)

Corticosteroid Pulse Therapy for Graves' Ophthalmopathy Reduces the Relapse Rate of Graves' Hyperthyroidism
por: Le Moli, Rosario, et al.
Publicado: (2020)

Emerging Insights Into the Role of Epigenetics and Gut Microbiome in the Pathogenesis of Graves’ Ophthalmopathy
por: Wang, Yan, et al.
Publicado: (2022)

Graves’ Ophthalmopathy in the Setting of Primary Hypothyroidism
por: Alajmi, Sarah, et al.
Publicado: (2022)

Efficacy and Safety of Different Intravenous Glucocorticoid Regimens in the Treatment of Graves' Ophthalmopathy: A Meta-Analysis
por: Chen, Jing, et al.
Publicado: (2021)

Monoclonal antibodies for the treatment of Graves’ ophthalmopathy: A systematic review and meta-analysis
por: Fatani, Wed A., et al.
Publicado: (2023)

Integrative Analysis of Proteomics and DNA Methylation in Orbital Fibroblasts From Graves’ Ophthalmopathy
por: Virakul, Sita, et al.
Publicado: (2021)

Intravenous Glucocorticoid Treatment for Korean Graves' Ophthalmopathy Patients
por: Ahn, Hwa Young, et al.
Publicado: (2020)

An Interesting Case of Euthyroid Graves’ Ophthalmopathy, With Negative Thyroid-Stimulating Hormone Receptor Antibodies
por: Moeen, Zunera, et al.
Publicado: (2021)

Autophagy in graves’ ophthalmopathy
por: Chen, Yu-Qing, et al.
Publicado: (2023)

Dihydroartemisinin Exerts Antifibrotic and Anti-Inflammatory Effects in Graves’ Ophthalmopathy by Targeting Orbital Fibroblasts
por: Yang, Shenglan, et al.
Publicado: (2022)

Efficacy and safety of tripterygium glycosides for active moderate to severe Graves’ ophthalmopathy: a randomised, observer-masked, single-centre trial
por: Ye, Xiaozhen, et al.
Publicado: (2020)

Prognostic significance of thyroid-stimulating hormone receptor antibodies in moderate-to-severe graves’ orbitopathy
por: Park, Jungyul, et al.
Publicado: (2023)

FRI547 Orbital Surgery In Moderate-To-Severe Graves´Ophthalmopathy: Institutional Experience
por: Delfino, Laura, et al.
Publicado: (2023)

Thyroid antibody-negative euthyroid Graves’ ophthalmopathy
por: Tabasum, Arshiya, et al.
Publicado: (2016)

Microarray Data of Lacrimal Gland Implicates Dysregulated Protein Processing in Endoplasmic Reticulum in Graves’ Ophthalmopathy
por: Tu, Wenling, et al.
Publicado: (2021)

Retraction: Efficacy and safety of tripterygium glycosides for active moderate to severe Graves’ ophthalmopathy: a randomised, observer-masked, single-centre trial
por: Ye, Xiaozhen, et al.
Publicado: (2021)

Use of Rituximab After Orbital Decompression Surgery in Two Grave’s Ophthalmopathy Patients Progressing to Optic Neuropathy
por: Zhang, Benping, et al.
Publicado: (2020)

Efficacy and Safety of 6-Weekly versus 12-Weekly Intravenous Methylprednisolone in Moderate-to-Severe Active Thyroid-Associated Ophthalmopathy
por: Lai, Kenneth K. H., et al.
Publicado: (2023)

Evidence That Baseline Levels of Low-Density Lipoproteins Cholesterol Affect the Clinical Response of Graves’ Ophthalmopathy to Parenteral Corticosteroids
por: Naselli, Adriano, et al.
Publicado: (2020)

Immunological Aspects of Graves' Ophthalmopathy
por: Łacheta, Dominika, et al.
Publicado: (2019)

Efficacy and safety of tripterygium glycosides for Graves ophthalmopathy: A systematic review and meta-analysis
por: Liu, Xiaowei, et al.
Publicado: (2019)

The Influence of Juvenile Graves' Ophthalmopathy on Graves' Disease Course
por: Jankauskiene, Jurate, et al.
Publicado: (2017)

Rituximab therapy in steroid-resistant severe hypothyroid Grave's ophthalmopathy
por: Pandit, Aditi, et al.
Publicado: (2013)

Graves' Ophthalmopathy: A Review of Immunogenetics
por: Khalilzadeh, Omid, et al.
Publicado: (2011)

Update on the medical treatment of Graves’ ophthalmopathy
por: Griepentrog, Gregory J, et al.
Publicado: (2009)

Radiotherapy in the treatment of Graves ophthalmopathy—to do it or not?
por: Zygulska, Aneta
Publicado: (2009)

Graves’ Ophthalmopathy Misdiagnosed as Relapsing Conjunctivitis
por: Chatziralli, Irini P., et al.
Publicado: (2010)

Imaging Evaluation of the Orbit in Graves Ophthalmopathy
por: SAS, T.N., et al.
Publicado: (2015)

Precision Medicine in Graves’ Disease and Ophthalmopathy
por: Elia, Giusy, et al.
Publicado: (2021)

Orbital endoscopic decompression in Graves Ophthalmopathy
por: Lima, Wilma Terezinha Anselmo, et al.
Publicado: (2015)

Therapy With Different Dose Regimens of Rituximab in Patients With Active Moderate-To-Severe Graves’ Orbitopathy
por: Campi, Irene, et al.
Publicado: (2022)

Therapy With Intravenous Methylprednisolone Pulses Is Associated With Loss of Bone Microarchitecture in Trabecular Bone Score -Assessment Among Patients With Moderate-to-Severe Graves’ Orbitopathy: A Pilot Study
por: Rymuza, Joanna, et al.
Publicado: (2022)

Evaluation of Quality of Life in the Brazilian Graves' Disease Population: Focus on Mild and Moderate Graves' Orbitopathy Patients
por: Villagelin, Danilo, et al.
Publicado: (2019)

Predictive Factors of Development of Graves' Ophthalmopathy for Patients with Juvenile Graves' Disease
por: Jarusaitiene, Dalia, et al.
Publicado: (2016)

Comparative Evaluation of Oculometric Variables in Graves’ Ophthalmopathy
por: Miot, Hélio Amante, et al.
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_lln4vnt7hovhup0eips4469bff